Hummingbird Bioscience was founded in 2015 to develop better ways of generating novel therapeutic antibody-based drugs. Using rational, systems biology approaches the aim of the company is to generate therapeutic antibodies which can be deployed in precision medicine.
To further this goal the company is utilizing cutting edge single cell profiling coupled with expertise in high throughput sequencing, bioinformatics and structural biology to enable our drugs to be used in the right patient at the right time.
The company has over 20 employees with operations in JLABS Houston, South San Francisco, and in Singapore.
Chief Executive Officer - Piers Ingram, PhD completed his PhD in Systems Biology at Imperial College London, funded by the Wellcome Trust and subsequently held several roles in academia, including as a research group leader at Imperial College, before moving to work in biopharma R&D consulting and then commercial strategy at Sanofi. Seeing the exciting progress in systems biology and immunology over the last decade, Piers co-founded Hummingbird Bioscience in order to apply these advances to drug discovery and development. Piers also holds an MBA from INSEAD.
Chief Scientific Officer - Jerome Boyd-Kirkup, PhD is the Co-Founder and Chief Scientific Officer responsible for overseeing the development of new technologies and intellectual property for drug discovery and development. Jerome is a molecular systems biologist with extensive experience in basic and applied translational science at the interface of
computational and wet lab biology in the context of human disease at top institutions in the UK and China. He holds a Bachelor's and Master's degree in
Biochemistry from Imperial College London and a PhD in Molecular Biology from Cambridge University.
Chief Medical Officer (Consultant) - Eric Rowinsky, M.D. has more than 25 years of experience managing clinical trials and developing drugs in oncology, including leading the Food and Drug Administration approval of Erbitux® for head and neck and colorectal cancers and advancing eight other biological therapeutics through clinical development while at ImClone. Dr Rowinsky was previously the Chief Medical Officer for Imclone Systems and Stemline. He currently serves on the Board of Directors of Biogen Idec Inc., Fortress Bio, Verastem, Biophytis, Rgenix and is an Adjunct Professor at New York University School of Medicine.
Chief Technology Officer- Konrad Paszkiewicz, PhD overseeing structural biology, computational genomics, machine learning and internal platform technologies. Konrad has held several academic positions including Director of the Wellcome Trust Centre for Biomedical Informatics at the University of Exeter, UK and was the head of the University of Exeter Sequencing and Genomics facility. He is an author on over 45 peer reviewed publications and has been an invited speaker and faculty of several renowned scientific workshops and seminar series. He holds an MSci in Physics and a PhD in Bioinformatics from Imperial College, London.
Scientific Advisory Board
Hummingbird Bioscience is advised by world leaders in the fields of immunology, oncology and protein engineering & production
James P. Allison, PhD serves as chair of The University of Texas MD Anderson Cancer Center Department of Immunology. Dr. Allison has a longstanding interest in mechanisms of T cell development and activation, the development of novel strategies for tumor immunotherapy. His research led to the development of ipilimumab, which was approved in 2011 by the FDA for the treatment of metastatic melanoma. Most recently, Dr. Allison was awarded the 2018 Nobel Prize in Physiology or Medicine jointly with Dr. Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation.
Padmanee Sharma, M.D. PhD is a leading cancer immunotherapy \scientist. Dr Sharma currently serves as co-director of the Parker Institute for Cancer Immumotherapy and as Professor in the departments of Genitourinary Medical Oncology and Immunology at The University of Texas MD Anderson Cancer Center. A co-founder of Jounce Therapeutics, she is a medical oncologist and immunologist, and is the principal investigator of several immunotherapy clinical trials, which allow her to investigate immune responses and pathways critical for eliciting anti-tumor responses which provide clinical benefit in cancer patients.
Jianzhu Chen, PhD is Professor of Biology at Koch Institute for Integrative Cancer Research and Department of Biology at Massachusetts Institute of Technology (MIT). He was the lead Principle Investigator of the Infectious Disease Interdisciplinary Research Group of Singapore-MIT Alliance for Research and Technology (SMART). Dr Chen's research seeks fundamental understanding of the immune system as well as its application in disease intervention. Recently, his research activity has focused on T cells and macrophages in immunity and diseases and cancer immunotherapy.
Wei Yang, PhD is Director of Target Discovery at the Institute for Protein Innovation at Harvard University.
Previously, Wei Yang served as Director of Molecular Biology at Novo Nordisk Research Centre China. He led an international team that successfully produced and screened for interactions between all human secreted proteins and single transmembrane cell surface proteins. This receptor-ligand de-orphaning effort identified the previously unknown receptors for GDF15 and VISTA, which are novel therapeutic targets for obesity and cancer, respectively. Dr Yang received B.S. and M.S. degrees from Jilin University and a PhD. from Peking University.
Board of Directors
In addition to the company founders, Chik Wai Chiew and Victor E. Tong serve as members of the Board of Directors
Chik Wai Chiew is the CEO and Executive Director of Heritas Capital Management. He has more than 20 years of experience in global investment management and strategic business development, having been active in leading various companies on transformational growth strategies, fund raising and M&A. He initiated Heritas Venture Fund in 2017 which has since invested in digital health, insuretech, diagnostics, and health foodtech etc. Wai Chiew was awarded the Glaxo-EDB scholarship and holds a BA in Economics from Cambridge University, UK; MA from Yale University, USA; and completed his EMBA at Cheung Kong Graduate School of Business, China.
Victor E. Tong is a partner at Decheng Capital focusing on investments in biotechnology and medical technology companies in the US and China. He has served on the boards of over ten successful Decheng backed companies leading to numerous aquisitions and IPOs. Prior to joining Decheng, Victor was a Principal at Bay City Capital and was a member of the founding team of Nevro. He was also an investment banker with Morgan Stanley advising healthcare companies on IPOs and specialized in strategic advisory work. Victor is a graduate of the University of California, Berkeley and holds a degree in Business Administration from the Haas School of Business.